Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon Feb 07, 2022 10:02am
274 Views
Post# 34404397

The competition needs our EAA !

The competition needs our EAA !https://altecomed.com/scientific-report-wroclaw-poland/


This is an open observational cohort study investigating the effectiveness of endotoxin elimination with the Alteco LPS Adsorber in patients with septic shock and endotoxemia. The aim of the study was to study whether the Alteco LPS Adsorber reduces organ failure and to assess the usefulness of the Spectral Diagnostics EAA (Endotoxin Activity Assay) in guiding the endotoxin elimination therapy.

but... perhaps


even more interesting than that....


"Interestingly 29% of the patients in the LPS Adsorber group with high EAA levels that responded well to the therapy did not have Gram negative bacterial infection. This indicates that endotoxaemia occurs even in the absence of Gram negative infection and the Alteco LPS Adsorber may improve clinical outcome in all patients with high EAA levels."

Matches the culture negative cohort that Spectral found.   No available treatment for this subset of Sepsis?  Up until now ...no...unless...

...you measure for endotoxins (using the EAA) and then remove them using a hemopurifirer, if they are at elevated levels !

MM




<< Previous
Bullboard Posts
Next >>